-
BUILDING TRUST: TRANSPARENCY AND STAKEHOLDER PARTICIPATION IN EU HTA
Aug 11, 2026, 17:15 PM -
EVOLVING CODING PRACTICES FOR PRIMARY IGA NEPHROPATHY IN GERMAN CLAIMS DATA: EVIDENCE FROM 2022-2024
Aug 11, 2026, 17:15 PM -
MAPPING PATIENT EXPERIENCES WITH GLP-1 RECEPTOR AGONISTS TO THE EQ-5D-5L FRAMEWORK USING ONLINE COMMUNITY FORUMS
Aug 11, 2026, 17:15 PM -
GOVERNANCE AND PRIORITIZATION FRAMEWORKS FOR EQUITABLE ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN THE MENA REGION: A CONSENSUS-DRIVEN APPROACH
Aug 11, 2026, 17:15 PM -
EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF ONCE-WEEKLY SOMAPACITAN AND SOMATROGON IN CHILDREN WITH GROWTH HORMONE DEFICIENCY: A SYSTEMATIC REVIEW
Aug 11, 2026, 17:15 PM -
CONSANGUINITY-ADJUSTED BUDGET IMPACT OF ORPHAN DRUG ACCESS FOR HEREDITARY TYROSINEMIA TYPE 1 IN MOROCCO: A PAYER-PERSPECTIVE MODEL
Aug 11, 2026, 17:15 PM -
ESTIMATING THE UK POPULATION ELIGIBLE FOR LATE-LINE MULTIPLE MYELOMA THERAPIES USING AN EPIDEMIOLOGICAL MODEL
Aug 11, 2026, 17:15 PM -
SOLAR: AN OBSERVATIONAL STUDY OF THE LONG-TERM EFFECTIVENESS OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN PEOPLE WITH CYSTIC FIBROSIS USING DATA FROM THE FRENCH CYSTIC FIBROSIS REGISTRY—IMPACT ON QUALITY OF LIFE AND HEALTH UTILITY VALUES
Aug 11, 2026, 17:15 PM -
FINANCIAL IMPACT OF BUNDLED CONTRACTS IN HEMODIALYSIS: A TOTAL COST OF OWNERSHIP (TCO) CASE STUDY OF A REGION IN SWEDEN
Aug 11, 2026, 17:15 PM -
CHARACTERIZING FGFR BIOMARKER TESTING IN METASTATIC UROTHELIAL CARCINOMA THROUGH NORSTELLALINQ LINKED CLAIMS AND ELECTRONIC HEALTH RECORDS, INCLUDING CLINICAL NOTES WITH HUMAN-IN-THE-LOOP LLM EXTRACTION
Aug 11, 2026, 17:15 PM -
TIME TO REIMBURSEMENT OF MULTIPLE SCLEROSIS THERAPIES IN POLAND ANALYSIS OF HTA SUBMISSION AND REIMBURSEMENT DECISIONS
Aug 11, 2026, 17:15 PM -
PRICE NEGOTIATION FOR HIGH-COST THERAPIES: A REVIEW OF THEORIES, STRATEGIES AND FACTORS INFLUENCING BARGAINING POWER
Aug 11, 2026, 17:15 PM -
CAPTURING THE DOWNSIDE: A TARGETED REVIEW OF ADVERSE EVENT COSTS AND DISUTILITY VALUES IN NICE APPRAISALS
Aug 11, 2026, 17:15 PM -
EU HTA IN PRACTICE: MEMBER STATE READINESS AND EARLY LESSONS FROM THE FIRST JCA REPORTS
Aug 11, 2026, 17:15 PM -
PHARMACEUTICAL TURNOVER BY ANATOMICAL THERAPEUTIC CHEMICAL (ATC) MAIN GROUPS IN ESTONIA BETWEEN 2012 AND 2024: AN ANALYSIS UTILIZING STATE AGENCY OF MEDICINES STATISTICAL YEARBOOK DATA
Aug 11, 2026, 17:15 PM -
VALUE DATA STUDI: A MODULAR HOSPITAL-PHARMACY METHODOLOGY TO QUANTIFY COST SAVINGS FROM CLINICAL TRIAL DRUG MANAGEMENT WITHIN AN INTEGRATED PHARMACEUTICAL DATA ECOSYSTEM
Aug 11, 2026, 17:15 PM -
REPORTING POPULATION NORMS AND SOCIOECONOMIC INEQUALITIES IN SELF-REPORTED HEALTH USING EQ-5D-5L: RESULTS FROM MULTICOUNTRY GENERAL POPULATION SURVEYS
Aug 11, 2026, 17:15 PM -
FEASIBILITY OF IDENTIFYING GENOTYPE-DEFINED DUCHENNE MUSCULAR DYSTROPHY POPULATIONS USING HUMAN-IN-THE-LOOP LLM AND LINKED CLINICAL NOTES FROM NORSTELLALINQ EHR
Aug 11, 2026, 17:15 PM -
TELEMEDICINE COST SAVINGS ARE CONDITIONAL RATHER THAN AUTOMATIC: A SYSTEMATIC REVIEW OF ECONOMIC EVIDENCE AND ITS IMPLICATIONS FOR REMOTE AND UNDERSERVED HEALTH SYSTEMS
Aug 11, 2026, 17:15 PM -
DEVELOPMENT OF A NEW COST-EFFECTIVENESS MODEL FOR CHRONIC HEPATITIS B VIRUS INFECTION BASED ON THE B-WELL TRIAL: VALIDATION OF HYBRID COHORT MODEL APPROACH
Aug 11, 2026, 17:15 PM
